Shizuoka Cancer Center

Shizuoka, Sunto-gun 411-8777

4 studies enrolling now · 7 studies all time

What they study most

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Extrapulmonary Neuroendocrine Cancer (epNEC), Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Head and Neck Squamous Cell Carcinoma, Large Cell Neuroendocrine Lung Carcinoma, Lung Cancer, Non-squamous, Non-small Cell, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumours

Studies at this site

• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Recruiting now
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers — Starting soon
• A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone — Running, not enrolling
• Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — Running, not enrolling
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed